Biostock interviews Chordate Medical’s Medical Director Jan Hermansson about the company’s post-market study PM010, which was recently initiated.
“Since this is an open study, we will be able to analyse the results on an ongoing basis. When we have a sufficient number of patients who have been on treatment long enough, we will conduct interim analyses […] We have selected clinics with a higher patient flow that did not participate in 007. Recognizing the challenges of patient recruitment for studies, we sought clinics with a substantial pool of patients to choose from. Additionally, it has been crucial that both the clinic’s management and healthcare team express a clear interest in our drug-free treatment alternative”, says Jan Hermansson to Biostock.